4I6F

Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.321 
  • R-Value Work: 0.235 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce alpha-synuclein phosphorylation in rat brain.

Aubele, D.L.Hom, R.K.Adler, M.Galemmo, R.A.Bowers, S.Truong, A.P.Pan, H.Beroza, P.Neitz, R.J.Yao, N.Lin, M.Tonn, G.Zhang, H.Bova, M.P.Ren, Z.Tam, D.Ruslim, L.Baker, J.Diep, L.Fitzgerald, K.Hoffman, J.Motter, R.Fauss, D.Tanaka, P.Dappen, M.Jagodzinski, J.Chan, W.Konradi, A.W.Latimer, L.Zhu, Y.L.Sham, H.L.Anderson, J.P.Bergeron, M.Artis, D.R.

(2013) Chemmedchem 8: 1295-1313

  • DOI: 10.1002/cmdc.201300166
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of α-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors o ...

    Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of α-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors of Plk-2 were obtained from a structure-guided drug discovery approach driven by the first reported Plk-2-inhibitor complexes. The best of these compounds showed excellent isoform and kinome-wide selectivity, with physicochemical properties sufficient to interrogate the role of Plk-2 inhibition in vivo. One such compound significantly decreased phosphorylation of α-synuclein in rat brain upon oral administration and represents a useful probe for future studies of this therapeutic avenue toward the potential treatment of Parkinson's disease.


    Organizational Affiliation

    Molecular Discovery, Elan Pharmaceuticals, 180 Oyster Point Boulevard, South San Francisco, CA 94080, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Serine/threonine-protein kinase PLK2
A
308Homo sapiensMutation(s): 7 
Gene Names: PLK2 (SNK)
EC: 2.7.11.21
Find proteins for Q9NYY3 (Homo sapiens)
Go to Gene View: PLK2
Go to UniProtKB:  Q9NYY3
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
1C7
Query on 1C7

Download SDF File 
Download CCD File 
A
(7R)-8-cyclopentyl-7-ethyl-5-methyl-2-(2-phenyl-1H-imidazol-1-yl)-7,8-dihydropteridin-6(5H)-one
C23 H26 N6 O
JMDRAMDTWLAOHD-GOSISDBHSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
1C7IC50: 5 nM (97) BINDINGDB
1C7IC50: 5 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.321 
  • R-Value Work: 0.235 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 103.824α = 90.00
b = 60.123β = 107.14
c = 53.119γ = 90.00
Software Package:
Software NamePurpose
HKL-2000data collection
HKL-2000data reduction
HKL-2000data scaling
REFMACrefinement
AMoREphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2012-11-29 
  • Released Date: 2013-11-20 
  • Deposition Author(s): Pan, H.

Revision History 

  • Version 1.0: 2013-11-20
    Type: Initial release